News & Updates

SGLT2i/DPP4i fixed-dose combination in a young patient with T2D and stage 4 CKD

05 Feb 2025 by

A 36-year-old male with young-onset type 2 diabetes (T2D), hypertension, and stage 4 chronic kidney disease (CKD) presented on 31 March 2023. He was an ex-smoker of 15 years and an ex-drinker, with a family history of diabetes, hypertension, and familial hypercholesterolaemia.

SGLT2i/DPP4i fixed-dose combination in a young patient with T2D and stage 4 CKD

05 Feb 2025

Use of an oral ACL inhibitor in two diabetic patients with hypercholesterolaemia and high/very high CV risk

03 Feb 2025 by

A 62-year-old nonsmoking Chinese man with metabolic syndrome (MES; hypertension, obesity, hypercholesterolaemia) and mild hyperuricaemia presented with type 2 diabetes (T2D; HbA_1c, 8.4 percent) in October 2018. His only baseline medication was candesartan 8 mg QD.

Use of an oral ACL inhibitor in two diabetic patients with hypercholesterolaemia and high/very high CV risk

03 Feb 2025

Early SGLT2i initiation stalls CKD progression, may delay dialysis

20 Jan 2025 by

Empagliflozin’s recently approved chronic kidney disease (CKD) indication expands the spectrum of patients with cardio-renal-metabolic (CRM) conditions who may benefit from treatment. At the 26^th Diabetes and Cardiovascular Risk Factors – East Meets West Symposium, Dr Ted Wu, Director of the Diabetes Centre, Royal Prince Alfred Hospital in Sydney, Australia, and Honorary Professor, Shijiazhuang Diabetes Hospital, Hebei, China, highlighted empagliflozin’s benefits in CKD, type 2 diabetes (T2D) and heart failure (HF), and discussed how early initiation of empagliflozin may stall CKD progression and delay dialysis.

Early SGLT2i initiation stalls CKD progression, may delay dialysis

20 Jan 2025

[Infographics] ARNI: First-line RASI in 4-pillar GDMT for HFrEF

15 Jan 2025

2024 American College of Cardiology’s Expert Consensus Decision Pathway for Treatment of Heart Failure with Reduced Ejection Fraction (HFrEF), the most recent international guidance on HFrEF treatment, recommends angiotensin receptor/neprilysin inhibitor (ARNI; ie, sacubitril/valsartan) as the preferred renin-angiotensin system inhibitor (RASI), which should be used as first-line therapy whenever possible. Emphasis is placed on initiating and titrating guideline-directed medical therapy (GDMT) early and rapidly. Here is why and how.

[Infographics] ARNI: First-line RASI in 4-pillar GDMT for HFrEF

15 Jan 2025

Early detection of PAH in connective tissue diseases: Why and how?

27 Dec 2024 by

Pulmonary arterial hypertension (PAH) is a severe complication of connective tissue diseases (CTDs). At the International Conference of Chinese Rheumatologists (ICCR) 2024, Dr Yeon-Ah Lee of the Kyung Hee University, Seoul, South Korea, emphasized the importance of screening and early detection of PAH in patients with CTDs and provided practical guidance for rheumatologists on screening for CTD-PAH, particularly in patients with systemic sclerosis (SSc) and systemic lupus erythematosus (SLE).

Early detection of PAH in connective tissue diseases: Why and how?

27 Dec 2024

What’s new, what’s hot in diabetes management: Snippets from ATTD-ASIA

25 Dec 2024

ATTD-ASIA 2024, held recently in Singapore, was a huge success, with nearly 800 delegates from 49 countries gracing the event. ATTD-Asia 2024 chair, Professor Moshe Phillip, said the event brought together top diabetes experts to ensure patients can access the latest technologies and treatments for diabetes. MIMS Doctor reports highlights and snippets from the conference.

What’s new, what’s hot in diabetes management: Snippets from ATTD-ASIA

25 Dec 2024

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

10 Dec 2024

The post-pandemic burden of COVID-19 remains significant in adults. Four studies from IDWeek 2024 highlight the benefits of nirmatrelvir-ritonavir (NMV/r) for high-risk adults with SARS-CoV-2 immunity and link chronic conditions to COVID-19 hospitalization. Identifying high-risk patients and using NMV/r in outpatient settings can reduce severe outcomes.

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

10 Dec 2024

First-line use of SGLT2 inhibitor as GDMT in a patient with HFpEF

09 Dec 2024 by

A 75-year-old female with a history of hypertension, diabetes, hyperlipidaemia, paroxysmal atrial fibrillation treated with apixaban (5 mg BID), and tachy-brady syndrome (for which a pacemaker was implanted in August 2022) was hospitalized due to acute shortness of breath (SoB) in November 2022.

First-line use of SGLT2 inhibitor as GDMT in a patient with HFpEF

09 Dec 2024

Clinical considerations for patients at high risk for progression to severe COVID-19

07 Dec 2024

COVID-19 has not gone away. New contagious variants continue to be a leading cause of death, with underlying conditions still influencing the risk of COVID-19 hospitalizations, said Dr Ali Hassoun, Clinical Professor of Medicine and infectious disease specialist at Crestwood Medical Center, Huntsville, Alabama, US, who spoke at a Pfizer-sponsored session during IDWeek 2024.

Clinical considerations for patients at high risk for progression to severe COVID-19

07 Dec 2024

The role of treat-to-target in inflammatory arthritis: Addressing cardiovascular risk and evaluating the benefit-risk profile of upadacitinib

04 Nov 2024

In this article, Professor Tam discusses her management approach to optimising outcomes in patients with inflammatory arthritis. She explores the role of the treat-to-target approach, emphasizes the importance of early disease control in reducing cardiovascular risk and evaluates the benefit-risk analysis of upadacitinib.

The role of treat-to-target in inflammatory arthritis: Addressing cardiovascular risk and evaluating the benefit-risk profile of upadacitinib

04 Nov 2024

News & Updates

Filter by Specialty:

Specialty:

SGLT2i/DPP4i fixed-dose combination in a young patient with T2D and stage 4 CKD

SGLT2i/DPP4i fixed-dose combination in a young patient with T2D and stage 4 CKD

Use of an oral ACL inhibitor in two diabetic patients with hypercholesterolaemia and high/very high CV risk

Use of an oral ACL inhibitor in two diabetic patients with hypercholesterolaemia and high/very high CV risk

Early SGLT2i initiation stalls CKD progression, may delay dialysis

Early SGLT2i initiation stalls CKD progression, may delay dialysis

[Infographics] ARNI: First-line RASI in 4-pillar GDMT for HFrEF

[Infographics] ARNI: First-line RASI in 4-pillar GDMT for HFrEF

Early detection of PAH in connective tissue diseases: Why and how?

Early detection of PAH in connective tissue diseases: Why and how?

What’s new, what’s hot in diabetes management: Snippets from ATTD-ASIA

What’s new, what’s hot in diabetes management: Snippets from ATTD-ASIA

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

First-line use of SGLT2 inhibitor as GDMT in a patient with HFpEF

First-line use of SGLT2 inhibitor as GDMT in a patient with HFpEF

Clinical considerations for patients at high risk for progression to severe COVID-19

Clinical considerations for patients at high risk for progression to severe COVID-19

The role of treat-to-target in inflammatory arthritis: Addressing cardiovascular risk and evaluating the benefit-risk profile of upadacitinib

The role of treat-to-target in inflammatory arthritis: Addressing cardiovascular risk and evaluating the benefit-risk profile of upadacitinib